Managing Data Privacy Risks in Biotech: Insights from 23andMe’s Downfall
In March 2025, 23andMe, a notable player in the biotech sector known for genetic testing, declared Chapter 11 bankruptcy, exposing the vulnerabilities that surround firms handling sensitive genetic data. This drastic step followed a credential-stuffing attack in 2023, which compromised the genetic information of approximately 6.4 million users. As the…